

1166029

SEC
Mail Processing
Section

SEU

FORM D

NOV 25 2008

OMB APPROVAL
OMB Number: 3235-0076
Expires: October 31, 2008
Estimated average burden hours per response: 4.00

Notice of Exempt
Offering of Securities

U.S. Securities and Exchange Commission
Washington, DC 20549

(See instructions beginning on page 5)

103

Intentional misstatements or omissions of fact constitute federal criminal violations. See 18 U.S.C. 1001.

Item 1. Issuer's Identity

Name of Issuer

QuatRx Pharmaceuticals Company

Jurisdiction of Incorporation/Organization

Delaware

Year of Incorporation/Organization

(Select one)

☒ Over Five Years Ago

☐ Within Last Five Years
(specify year)

☐ Yet to Be Formed

Previous Name(s)

☐ None

Pegasus Pharmaceuticals Company

Entity Type (Select one)

☒ Corporation

☐ Limited Partnership

☐ Limited Liability Company

☐ General Partnership

☐ Business Trust

☐ Other (Specify):

(If more than one issuer is filing this notice, check this box ☐ and identify additional issuer(s) by attaching Items 1 and 2 Continuation Page(s).)

Item 2. Principal Place of Business and Contact Information

Street Address 1

777 East Eisenhower Parkway, Suite 100

City

Ann Arbor

State/Province/Country

MI

Street Address 2

ZIP/Postal Code

48108

Phone No.

734-913-9900

PROCESSED

DEC 03 2008

THOMSON REUTERS

Item 3. Related Persons

Last Name

Zerbe

First Name

Robert

Middle Name

L.

Street Address 1

777 East Eisenhower Parkway, Suite 100

City

Ann Arbor

State/Province/Country

MI

Street Address 2

ZIP/Postal Code

48108

Relationship(s): ☒ Executive Officer ☒ Director ☐ Promoter

Clarification of Response (if Necessary)



08061474

(Identify additional related persons by checking this box ☒ and attaching Item 3 Continuation Page(s).)

Item 4. Industry Group (Select one)

☐

Agriculture

Banking and Financial Services

☐ Commercial Banking

☐ Insurance

☐ Investing

☐ Investment Banking

☐ Pooled Investment Fund

If selecting this Industry group, also select one fund type below and answer the question below:

☐ Hedge Fund

☐ Private Equity Fund

☐ Venture Capital Fund

☐ Other Investment Fund

Is the issuer registered as an investment company under the Investment Company Act of 1940? ☐ Yes ☐ No

☐ Other Banking & Financial Services

☐

Business Services

Energy

☐ Electric Utilities

☐ Energy Conservation

☐ Coal Mining

☐ Environmental Services

☐ Oil & Gas

☐ Other Energy

Health Care

☐ Biotechnology

☐ Health Insurance

☐ Hospitals & Physicians

☒ Pharmaceuticals

☐ Other Health Care

☐

Manufacturing

Real Estate

☐ Commercial

☐

Construction

☐

REITS & Finance

☐

Residential

☐

Other Real Estate

☐

Retailing

☐

Restaurants

☐

Technology

☐

Computers

☐

Telecommunications

☐

Other Technology

☐

Travel

☐

Airlines & Airports

☐

Lodging & Conventions

☐

Tourism & Travel Services

☐

Other Travel

☐

Other

Item 5. Issuer Size (Select one)

Revenue Range (for issuer not specifying "hedge" or "other investment" fund in Item 4 above)

- ☐ No Revenues
- ☐ \$1 - \$1,000,000
- ☐ \$1,000,001 - \$5,000,000
- ☐ \$5,000,001 - \$25,000,000
- ☐ \$25,000,001 - \$100,000,000
- ☐ Over \$100,000,000
- ☒ Decline to Disclose
- ☐ Not Applicable

OR

Aggregate Net Asset Value Range (for issuer specifying "hedge" or "other investment" fund in Item 4 above)

- ☐ No Aggregate Net Asset Value
- ☐ \$1 - \$5,000,000
- ☐ \$5,000,001 - \$25,000,000
- ☐ \$25,000,001 - \$50,000,000
- ☐ \$50,000,001 - \$100,000,000
- ☐ Over \$100,000,000
- ☒ Decline to Disclose
- ☐ Not Applicable

Item 6. Federal Exemptions and Exclusions Claimed (Select all that apply)

- ☐ Rule 504(b)(1) (not (i), (ii) or (iii))
- ☐ Rule 504(b)(1)(i)
- ☐ Rule 504(b)(1)(ii)
- ☐ Rule 504(b)(1)(iii)
- ☐ Rule 505
- ☒ Rule 506
- ☐ Securities Act Section 4(6)

Investment Company Act Section 3(c)

- ☐ Section 3(c)(1)
- ☐ Section 3(c)(2)
- ☐ Section 3(c)(3)
- ☐ Section 3(c)(4)
- ☐ Section 3(c)(5)
- ☐ Section 3(c)(6)
- ☐ Section 3(c)(7)

- ☐ Section 3(c)(9)
- ☐ Section 3(c)(10)
- ☐ Section 3(c)(11)
- ☐ Section 3(c)(12)
- ☐ Section 3(c)(13)
- ☐ Section 3(c)(14)

Item 7. Type of Filing☒ New Notice **OR** ☐ AmendmentDate of First Sale in this Offering: **OR** ☐ First Sale Yet to Occur**Item 8. Duration of Offering**Does the issuer intend this offering to last more than one year? ☐ Yes ☒ No**Item 9. Type(s) of Securities Offered (Select all that apply)**

- ☐ Equity
- ☒ Debt
- ☐ Option, Warrant or Other Right to Acquire Another Security
- ☐ Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security
- ☐ Pooled Investment Fund Interests
- ☐ Tenant-in-Common Securities
- ☐ Mineral Property Securities
- ☐ Other (Describe)

Item 10. Business Combination TransactionIs this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? ☐ Yes ☒ No

Clarification of Response (if Necessary)

Item 11. Minimum InvestmentMinimum investment accepted from any outside investor \$ **Item 12. Sales Compensation**

Recipient

Recipient CRD Number

☐ No CRD Number(Associated) Broker or Dealer ☐ None

(Associated) Broker or Dealer CRD Number

☐ No CRD Number

Street Address 1

Street Address 2

City

State/Province/Country

ZIP/Postal Code

States of Solicitation ☐ All States

☐ AL	☐ AK	☐ AZ	☐ AR	☐ CA	☐ CO	☐ CT	☐ DE	☐ DC	☐ FL	☐ GA	☐ HI	☐ ID
☐ IL	☐ IN	☐ IA	☐ KS	☐ KY	☐ LA	☐ ME	☐ MD	☐ MA	☐ MI	☐ MN	☐ MS	☐ MO
☐ MT	☐ NE	☐ NV	☐ NH	☐ NJ	☐ NM	☐ NY	☐ NC	☐ ND	☐ OH	☐ OK	☐ OR	☐ PA
☐ RI	☐ SC	☐ SD	☐ TN	☐ TX	☐ UT	☐ VT	☐ VA	☐ WA	☐ WV	☐ WI	☐ WY	☐ PR

(Identify additional person(s) being paid compensation by checking this box ☐ and attaching Item 12 Continuation Page(s).)**Item 13. Offering and Sales Amounts**

(a) Total Offering Amount

\$ OR ☐ Indefinite

(b) Total Amount Sold

\$ (c) Total Remaining to be Sold
(Subtract (a) from (b))\$ OR ☐ Indefinite

Clarification of Response (if Necessary)

Item 14. InvestorsCheck this box ☐ if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering:

Enter the total number of investors who already have invested in the offering:

Item 15. Sales Commissions and Finders' Fees Expenses

Provide separately the amounts of sales commissions and finders' fees expenses, if any. If an amount is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$

☐ Estimate

Clarification of Response (if Necessary)

Finders' Fees \$

☐ Estimate

Item 16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$ 0

☐ Estimate

Clarification of Response (if Necessary)

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and submitting this notice.

Terms of Submission. In Submitting this notice, each identified issuer is:

Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in accordance with applicable law, the information furnished to offerees.*

Irrevocably appointing each of the Secretary of the SEC and the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes; or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.

Certifying that, if the issuer is claiming a Rule 505 exemption, the issuer is not disqualified from relying on Rule 505 for one of the reasons stated in Rule 505(b)(2)(iii).

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.

Each identified issuer has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person. (Check this box ☐ and attach Signature Continuation Pages for signatures of issuers identified in Item 1 above but not represented by signer below.)

Issuer(s)

QuatRx Pharmaceutical Company

Name of Signer

Jeffrey M. Brinza

Signature



Title

General Counsel

Number of continuation pages attached:

3

Date

11-21-08

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Item 3 Continuation Page

Item 3. Related Persons (Continued)

Last Name	First Name	Middle Name
Nicholas	Christopher	
Street Address 1	Street Address 2	
c/o QuatRx Pharmaceuticals Company	777 East Eisenhower Parkway, Suite 100	
City	State/Province/Country	ZIP/Postal Code
Ann Arbor	MI	48108
Relationship(s): ☒ Executive Officer ☐ Director ☐ Promoter		
Clarification of Response (if Necessary)		

Last Name	First Name	Middle Name
Dombey	Stuart	P.
Street Address 1	Street Address 2	
c/o QuatRx Pharmaceuticals Company	777 East Eisenhower Parkway, Suite 100	
City	State/Province/Country	ZIP/Postal Code
Ann Arbor	MI	48108
Relationship(s): ☒ Executive Officer ☐ Director ☐ Promoter		
Clarification of Response (if Necessary)		

Last Name	First Name	Middle Name
Onn	Gary	
Street Address 1	Street Address 2	
c/o QuatRx Pharmaceuticals Company	777 East Eisenhower Parkway, Suite 100	
City	State/Province/Country	ZIP/Postal Code
Ann Arbor	MI	48108
Relationship(s): ☒ Executive Officer ☐ Director ☐ Promoter		
Clarification of Response (if Necessary)		

Last Name	First Name	Middle Name
Brinza	Jeffrey	M.
Street Address 1	Street Address 2	
c/o QuatRx Pharmaceuticals Company	777 East Eisenhower Parkway, Suite 100	
City	State/Province/Country	ZIP/Postal Code
Ann Arbor	MI	48108
Relationship(s): ☒ Executive Officer ☐ Director ☐ Promoter		
Clarification of Response (if Necessary)		

(Copy and use additional copies of this page as necessary.)

Item 3 Continuation Page

Item 3. Related Persons (Continued)

Last Name	First Name	Middle Name
Ehrlich	Christopher	B.
Street Address 1	Street Address 2	
c/o InterWest Partners	2710 Sand Hill Road, 2nd Floor	
City	State/Province/Country	ZIP/Postal Code
Menlo Park	CA	94025
Relationship(s): ☐ Executive Officer ☒ Director ☐ Promoter		
Clarification of Response (if Necessary)		

Last Name	First Name	Middle Name
Fox	Richard	P.
Street Address 1	Street Address 2	
c/o QuatRx Pharmaceuticals Company	777 East Eisenhower Parkway, Suite 100	
City	State/Province/Country	ZIP/Postal Code
Ann Arbor	MI	48108
Relationship(s): ☐ Executive Officer ☒ Director ☐ Promoter		
Clarification of Response (if Necessary)		

Last Name	First Name	Middle Name
Heron	Patrick	
Street Address 1	Street Address 2	
c/o Frazier Healthcare Ventures	70 Willow Road, Suite 200	
City	State/Province/Country	ZIP/Postal Code
Menlo Park	CA	94025
Relationship(s): ☐ Executive Officer ☒ Director ☐ Promoter		
Clarification of Response (if Necessary)		

Last Name	First Name	Middle Name
Hove	Anders	
Street Address 1	Street Address 2	
c/o Venrock	530 Fifth Avenue, 22nd Floor	
City	State/Province/Country	ZIP/Postal Code
New York	NY	10036
Relationship(s): ☐ Executive Officer ☒ Director ☐ Promoter		
Clarification of Response (if Necessary)		

(Copy and use additional copies of this page as necessary.)

Item 3 Continuation Page

Item 3. Related Persons (Continued)

Last Name	First Name	Middle Name
Moller	Christopher	B.
Street Address 1	Street Address 2	
c/o TL Ventures	435 Devon Park Drive, 700 Building	
City	State/Province/Country	ZIP/Postal Code
Wayne	PA	19087
Relationship(s): ☐ Executive Officer ☒ Director ☐ Promoter		
Clarification of Response (if Necessary)		

Last Name	First Name	Middle Name
Simon, III	Nicholas	
Street Address 1	Street Address 2	
c/o Clarus Ventures and MPM Bioventures III	200 Clarendon Street, 54th Floor	
City	State/Province/Country	ZIP/Postal Code
Boston	MA	02116
Relationship(s): ☐ Executive Officer ☒ Director ☐ Promoter		
Clarification of Response (if Necessary)		

Last Name	First Name	Middle Name
Watanabe	August	
Street Address 1	Street Address 2	
c/o QuatRx Pharmaceuticals Company	777 East Eisenhower Parkway, Suite 100	
City	State/Province/Country	ZIP/Postal Code
Ann Arbor	Mi	48108
Relationship(s): ☐ Executive Officer ☒ Director ☐ Promoter		
Clarification of Response (if Necessary)		

Last Name	First Name	Middle Name
Wiklund	Anders	P.
Street Address 1	Street Address 2	
c/o Wiklund International, Inc.	928 Sunset Ridge	
City	State/Province/Country	ZIP/Postal Code
Bridgewater	NJ	08807
Relationship(s): ☐ Executive Officer ☒ Director ☐ Promoter		
Clarification of Response (if Necessary)		

END